PROTAC-mediated DPP-4 degradation proposed as novel strategy for sustained glycemic control in Type 2 Diabetes.

Type 2 diabetes mellitus (T2DM) is characterized by diminished insulin responsiveness, often exacerbated by rapid degradation of glucagon-like peptide-1 (GLP-1). This crucial incretin hormone, vital for glucose homeostasis, is quickly cleaved by Dipeptidyl peptidase-4 (DPP-4), limiting its therapeutic efficacy. While small-molecule DPP-4 inhibitors exist for T2DM management, their benefits are moderate due to transient enzyme inhibition, failing to provide sustained GLP-1 protection and optimal glycemic control. A persistent inhibition strategy is needed to address this therapeutic gap.

This paper conceptually explores the application of proteolysis-targeting chimera (PROTAC) technology as a novel strategy for the sustained degradation of Dipeptidyl peptidase-4 (DPP-4). The authors propose PROTACs as an alternative to traditional small-molecule inhibitors, aiming to overcome the limitations of transient DPP-4 inhibition in type 2 diabetes mellitus (T2DM) management. The work outlines the theoretical framework for how PROTACs could achieve prolonged enzyme suppression, contrasting it with the reversible binding mechanisms of existing DPP-4 inhibitors.